title: Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
abstract: OBJECTIVE
  This study measured the human epididymis protein 4 (HE4) and CA125 levels in Chinese women with benign gynecological disorders.
  
  
  METHODS
  Sera were obtained from Chinese women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with HE4 and CA125 levels were compared.
  
  
  RESULTS
  There were 68 Chinese women with benign diseases. HE4 levels were less elevated than CA125 (1% V.S. 29%, P<0.001). The significant difference was observed in patients with endometriosis/endometriomas in which HE4 was not elevated patients and CA125 was elevated in 53% (P<0.001). Serum HE4 level was not elevated in patients with cystadenoma (0% V.S. 23%, P<0.001) and in patients with germ cell tumors (0% V.S. 5%, P<0.001).
  
  
  CONCLUSIONS
  HE4 was less elevated and more suitable as a biomarker than CA125 in chinese women with benign disease.
authors.affiliation: Department of Gynecology and Obstetrics, the Chinese PLA General Hospital.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Laboratory of Immunology, Institute of Basic Medical Sciences.
authors.forename: Chunxia
authors.initials: C
authors.lastname: Qiao
authors.affiliation: Department of Microbiology, College of Medical Sciences, Inner Mongolia Medical University.
authors.forename: Lian
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Gynecology and Obstetrics, Shanxi Tumor Hospital.
authors.forename: Xuye
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Gynecology and Obstetrics, the Chinese PLA General Hospital.
authors.forename: Yali
authors.initials: Y
authors.lastname: Li
mesh_terms: D000328:Adult; D044466:Asian People / Q000706:statistics & numerical data*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood / Q000378:metabolism*; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood / Q000175:diagnosis* / Q000208:ethnology; D006801:Humans; D008565:Membrane Proteins / Q000097:blood / Q000378:metabolism*; D008875:Middle Aged; D011237:Predictive Value of Tests; D011506:Proteins / Q000032:analysis / Q000378:metabolism*; D012372:ROC Curve; D012680:Sensitivity and Specificity; D000081102:WAP Four-Disulfide Core Domain Protein 2
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human
keywords: CA125; HE4; benign gynecological disease; biomarker
references.citation: Am J Obstet Gynecol. 2011 Oct;205(4):358.e1-6
references.pmid: 21722869
references.citation: Gynecol Oncol. 1992 Oct;47(1):87-92
references.pmid: 1427408
references.citation: Biol Reprod. 1991 Aug;45(2):350-7
references.pmid: 1686187
references.citation: World J Surg Oncol. 2010;8:28
references.pmid: 20398372
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6
references.pmid: 19134334
references.citation: J Natl Cancer Inst. 2006 Feb 1;98(3):172-80
references.pmid: 16449677
references.citation: Diagn Pathol. 2013;8:11
references.pmid: 23343214
references.citation: Hum Reprod. 2000 Jun;15(6):1261-5
references.pmid: 10831552
references.citation: Gynecol Oncol. 2012 Jun;125(3):667-72
references.pmid: 22426487
references.citation: N Engl J Med. 1983 Oct 13;309(15):883-7
references.pmid: 6310399
references.citation: Tumour Biol. 2010 Apr;31(2):113-9
references.pmid: 20358424
references.citation: Int J Cancer Suppl. 1988;3:61-7
references.pmid: 3209301
references.citation: J Ovarian Res. 2013 Jul 01;6(1):44
references.pmid: 23816286
references.citation: PLoS Med. 2008 Dec 2;5(12):e232
references.pmid: 19053170
references.citation: Gynecol Oncol. 2008 Feb;108(2):402-8
references.pmid: 18061248
references.citation: Obstet Gynecol. 2003 Sep;102(3):499-505
references.pmid: 12962932
references.citation: Oncogene. 2002 Apr 18;21(17):2768-73
references.pmid: 11965550
references.citation: Cancer Res. 2003 Jul 1;63(13):3695-700
references.pmid: 12839961
references.citation: Tumour Biol. 2011 Apr;32(2):265-71
references.pmid: 20953751
references.citation: Clin Chem. 2011 Nov;57(11):1534-44
references.pmid: 21933899
references.citation: Tumour Biol. 2010 Oct;31(5):411-5
references.pmid: 20490961
references.citation: Int J Mol Sci. 2011;12(1):627-32
references.pmid: 21340004
references.citation: Cancer. 2002 Nov 1;95(9):1886-93
references.pmid: 12404282
references.citation: Clin Biochem. 2011 Jul;44(10-11):884-8
references.pmid: 21549107
references.citation: Gynecol Oncol. 2010 Mar;116(3):378-83
references.pmid: 19945742
references.citation: Cancer. 1995 Nov 15;76(10 Suppl):2092-6
references.pmid: 8635006
references.citation: Tumour Biol. 2012 Oct;33(5):1335-9
references.pmid: 22528938
references.citation: Am J Obstet Gynecol. 2012 Apr;206(4):351.e1-8
references.pmid: 22284961
references.citation: Br J Cancer. 2001 Dec 14;85(12):1824-30
references.pmid: 11747321
references.citation: Ann Oncol. 1990 Jul;1(4):301-2
references.pmid: 2265140